Introduction: The SARS-CoV-2-associated infection (COVID-19) pandemic has caused widespread disease among all age groups, including children.Multisystem inflammatory syndrome in children (MIS-C) or pediatric inflammatory multisystem syndrome is a clinical syndrome, manifests ascytokine storm in children. Material and Methods: This is a retrospective case series study. Alldiagnosed cases as per diagnostic criteria of Centre for disease control and prevention, WHO and RCPCH,a total of 11 cases were included reported in the year 2021, at Adesh Institute of medical sciences and Research, Bathinda. Study has measured all the clinical and laboratory parameters andtreatment measures taken. Results: The age of presentation of the disease was between 6 months to 12.9 years.The history of fever was positive in all the patients. Other presenting symptoms were cough and cold, Respiratory difficulty, loss of appetite, diarrhoea, abdominal pain. Two patients had episodes of seizures and had undergone shock. One patient has a history of conjunctivitis and other one patient has developed rash.All the patients have raised CRP, elevated level of D-dimer and raised value of anti-SARS-CoV-2 antibodies.All the admittedcases have received injection Methylprednisolone, oxygen support, tab Aspirin and injectable antimicrobials. Most commonly used antimicrobial was ceftriaxone, Piperacillin and tazobactam, Amikacin, Meropenem, Colistin. Two patients with seizure attack have received antiepileptic, Levetiracetam, Fosphenytoin.Two of the patient has received inotropes, Fresh frozen plasma, Purified red blood cellss because of shock. Almost all patients have hospital stay of 5 days, two patient had history of stay of 15 days. All patients have responded well to the treatment. Conclusion: Our case series reports on clinical and laboratory findings of pediatric cases with MIS-C and displays a range of heterogeneous treatments. The hydration, antibacterial therapy, corticosteroids, IVIg has been the main stay of treatment.